Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
84.09
-0.62 (-0.73%)
At close: Sep 8, 2025, 4:00 PM
84.23
+0.14 (0.17%)
After-hours: Sep 8, 2025, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.34
Revenue / Employee
$848,213
Employees
75,000
Market Cap
210.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
MRK News
- 7 hours ago - Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (Sept. 2025) - Seeking Alpha
- 2 days ago - September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog - Seeking Alpha
- 4 days ago - Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 days ago - Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Business Wire
- 5 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 6 days ago - Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector - Business Wire
- 6 days ago - Merck's cholesterol drug meets main goal in late-stage trial - Reuters